 PRINCETON, N.J., April 30, 2021 GLOBE NEWSWIRE -- Agile Therapeutics, Inc. Nasdaq: AGRX, a womens healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla levonorgestrel and ethinyl estradiol transdermal system in women with BMI 25 kgm2 and women with BMI 25-30 kgm2 will be presented at the American College of Obstetricians and Gynecologists ACOG Annual Clinical and Scientific Meeting from April 30 May 2. 